Patient info Open main menu

Ultiva (Remifentanil Hydrochloride) for injection 2 mg – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Controlled drug (Schedule 2) Details

Medicine strength:
2 mg
Contains active substance:
Similar medicines:

Patient leaflet - Ultiva (Remifentanil Hydrochloride) for injection 2 mg

1 What Remifentanil is and what it is used for

Remifentanil powder for concentrate for solution for injection/infusion contains a medicine called remifentanil. This belongs to a group of medicines known as opioids.

Remifentanil is used together with other medicines called anaesthetics

  • to help put you to sleep before an operation
  • to keep you asleep and stop you feeling pain during an operation
  • to make you feel sleepy and stop you feeling pain while you receive treatment in an Intensive Care Unit.

2 What you need to know before you are given Remifentanil

Do not have remifentanil if:

  • you are allergic (hypersensitive) to remifentanil or any of the other ingredients of Remifentanil (listed in

    section 6)

  • you are allergic (hypersensitive) to any other pain-relieving medicines which are similar to fentanyl and which

    are related to the class of medicines known as opioids.

If you are not sure if any of the above apply to you, talk to your doctor, pharmacist or nurse before you are given remifentanil.

Tell your doctor before using remifentanil if:

  • You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or

    illegal drugs (“addiction”).

  • You are a smoker.
  • You have ever had problems with your mood (depression, anxiety or a personality disorder) or have been

    treated by a psychiatrist for other mental illnesses.

This medicine contains remifentanil which is an opioid medicine. Repeated use of opioid painkillers may result in the drug being less effective (you become accustomed to it). It may also lead to dependence and abuse which may result in life-threatening overdose. If you have concern that you may become dependent on this medicine, it is important that you consult your doctor.

Withdrawal reactions including rapid heartbeat, high blood pressure and restlessness have occasionally been reported when treatment with this medicine is stopped suddenly, particularly when treatment has lasted more than 3 days (see also section 4. Possible side effects). If you experience these symptoms, your doctor may re-introduce the medicine and gradually reduce the dose.

Warnings and precautions

Check with your doctor or pharmacist before you are given remifentanil if:

  • you are allergic (hypersensitive) to any other opioid medicines, such as morphine or codeine • you are over 65 years of age
  • you are dehydrated or have lost a lot of blood
  • you have been feeling weak or unwell
  • if you are overweight

If you are not sure if any of the above apply to you, talk to your doctor, pharmacist or nurse before you are given remifentanil.

Other medicines and Remifentanil

Please tell your doctor or pharmacist if you are taking or have recently taken or might take other medicines, including medicines obtained without a prescription. This includes herbal medicines. This is because remifentanil can work with other medicines to cause side effects.

In particular tell your doctor or pharmacist if you are taking:

  • medicines for your heart or blood pressure, such as beta-blockers (these include atenolol, metoprolol, carvedilol, propanolol and bisoprolol) or calcium channel blockers (these include amlodipine, diltiazem and nifedipine).
  • medicines for the treatment of depression such as Selective Serotonin Reuptake Inhibitors (SSRIs),

    Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Monoamine Oxidase Inhibitors (MAOIs). It is not recommended to use these medicines at the same time as this medicine as they may increase the risk of serotonin syndrome, a potentially life-threatening condition.

Concomitant use of remifentanil and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. The concomitant use of opioids and drugs used to treat epilepsy, nerve pain or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and may be life-threatening.

However if your doctor does prescribe remifentanil together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.

Please tell your doctor about all sedative medicines you are taking, and follow your doctor’s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.

This medicine with alcohol

After receiving this medicine, you should not drink alcohol until you have fully recovered.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.

If you are given this medicine during labour or close to childbirth, it can affect your baby’s breathing. You and your baby will be monitored for signs of excessive sleepiness and difficulty breathing.

Driving and using machines

If you are only staying in hospital for the day, your doctor will tell you how long to wait before leaving the hospital or driving a car. It can be dangerous to drive too soon after having an operation.

The medicine can affect your ability to drive as it may make you sleepy or dizzy.

  • Do not drive while taking this medicine until you know how it affects you.
  • It is an offence to drive if this medicine affects your ability to drive.
  • However, you would not be committing an offence if:

    o The medicine has been prescribed to treat a medical or dental problem and

    o You have taken it according to the instructions given by the prescriber or in the information provided with the medicine and

    o It was not affecting your ability to drive safely

Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.

This medicine contains Sodium

This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium free’.

3 How to use Remifentanil

How your injection is given

You will never be expected to give yourself this medicine. It will always be given to you by a person who is qualified to do so.

Remifentanil can be given:

  • as a single injection into your vein
  • as a continuous infusion into your vein. This is where the drug is slowly given to you over a longer period of time.

The way you are given the drug and the dose you receive will depend on:

  • your weight
  • the operation you have
  • how much pain you will be in
  • how sleepy the medical staff want you to be in the Intensive Care Unit.

The dose varies from one patient to another.

If you are given too much

The effects of remifentanil are carefully monitored throughout your operation and in intensive care, and appropriate action will be taken promptly if you receive too much.

After your operation

Tell your doctor or nurse if you are in pain. If you are in pain after your procedure, they will be able to give you other painkillers.

4 Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine.

Some people can be allergic to remifentanil. You must tell your doctor or nurse immediately if you have: Rare (may affect up to 1 in 1,000 people)

  • sudden wheeziness and chest pain or chest tightness
  • swelling of your eyelids, face, lips, mouth or tongue
  • a lumpy skin rash or ‘hives’ anywhere on the body
  • collapse.

0000000000

AW Version:

1

Page:

1 of 2

00002_0000152221
N/A

Market

United Kingdom

Number of Colours:

1

Table 2. Remifentanil injection Infusion Rates (ml/h) for a 20 micrograms/ml Solution

Infusion Rate (micrograms/kg/min)Patient Weight (kg)
5102030405060
0.01250.1880.3750.751.1251.51.8752.25
0.0250.3750.751.52.253.03.754.5
0.050.751.53.04.56.07.59.0
0.0751.1252.254.56.759.011.2513.5
0.11.53.06.09.012.015.018.0
0.152.254.59.013.518.022.527.0
0.23.06.012.018.024.030.036.0
0.253.757.515.022.530.037.545.0
0.34.59.018.027.036.045.054.0
0.355.2510.521.031.542.052.563.0
0.46.012.024.036.048.060.072.0

Table 3. Remifentanil injection Infusion Rates (ml/h) for a 25 micrograms/ml Solution

Infusion Rate

(micrograms/kg/min)

Patient Weight (kg)
102030405060708090100
0.01250.30.60.91.21.51.82.12.42.73.0
0.0250.61.21.82.43.03.64.24.85.46.0
0.051.22.43.64.86.07.28.49.610.812.0
0.0751.83.65.47.29.010.812.614.416.218.0
0.12.44.87.29.612.014.416.819.221.624.0
0.153.67.210.814.418.021.625.228.832.436.0
0.24.89.614.419.224.028.833.638.443.248.0

Table 4. Remifentanil injection Infusion Rates (ml/h) for a 50 micrograms/ml Solution

Infusion Rate

(micrograms/kg/min)

Patient Weight (kg)
30405060708090100
0.0250.91.21.51.82.12.42.73.0
0.051.82.43.03.64.24.85.46.0
0.0752.73.64.55.46.37.28.19.0
0.13.64.86.07.28.49.610.812.0
0.155.47.29.010.812.614.416.218.0
0.27.29.612.014.416.819.221.624.0
0.259.012.015.018.021.024.027.030.0
0.518.024.030.036.042.048.054.060.0
0.7527.036.045.054.063.072.081.090.0
1.036.048.060.072.084.096.0108.0120.0
1.2545.060.075.090.0105.0120.0135.0150.0
1.554.072.090.0108.0126.0144.0162.0180.0
1.7563.084.0105.0126.0147.0168.0189.0210.0
2.072.096.0120.0144.0168.0192.0216.0240.0

Table 5. Remifentanil injection Infusion Rates (ml/h) for a 250 micrograms/ml Solution

Infusion Rate

(micrograms/kg/min)

Patient Weight (kg)
30405060708090100
0.10.720.961.201.441.681.922.162.40
0.151.081.441.802.162.522.883.243.60
0.21.441.922.402.883.363.844.324.80
0.251.802.403.003.604.204.805.406.00
0.53.604.806.007.208.409.6010.8012.00
0.755.407.209.0010.8012.6014.4016.2018.00
1.07.209.6012.0014.4016.8019.2021.6024.00
1.259.0012.0015.0018.0021.0024.0027.0030.00
1.510.8014.4018.0021.6025.2028.8032.4036.00
1.7512.6016.8021.0025.2029.4033.6037.8042.00
2.014.4019.2024.0028.8033.6038.4043.2048.00

This leaflet was last revised in November 2023.

Severe allergic reactions can progress to life-threatening anaphylactic shock; Frequency not known (cannot be estimated from the available data) which include worsening of allergic signs, severe drop in blood pressure, heart beats quickly and/or fainting.

Tell your doctor as soon as possible if you notice any of the following:

Very common (may affect more than 1 in 10 people)

  • muscle stiffness
  • low blood pressure
  • feeling sick or being sick

Common (may affect up to 1 in 10 people)

  • slow heartbeat
  • shallow breathing or temporarily stop breathing
  • itching
  • Cough

Uncommon (may affect up to 1 in 100 people)

  • problems breathing (hypoxia)
  • constipation

Rare (may affect up to 1 in 1,000 people)

  • allergic reactions
  • heart stops beating

Not known (frequency cannot be estimated from the available data)

  • physical need for remifentanil (drug dependency) or the need for increasing doses over time to get the same

    effect (drug tolerance)

  • fits (seizures)
  • a type of irregular heartbeat (atrioventricular block)
  • Irregular heartbeat (arrhythmia)
  • Withdrawal syndrome (may manifest by the occurrence of the following side effects: increased heart rate, high

    blood pressure, feeling restless or agitated, nausea, vomiting, diarrhoea, anxiety, chills, tremor, and sweating)

Other side effects that can happen when you wake up after having an anaesthetic include: Common (may affect up to 1 in 10 people)

  • shivering
  • increases in blood pressure

Uncommon (may affect up to 1 in 100 people)

  • aches

Rare (may affect up to 1 in 1,000 people)

  • feeling very calm or drowsy (sedation)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www. mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5 How to store Remifentanil

  • Keep this medicine out of the sight and reach of children.
  • Do not use Remifentanil after the expiry date which is stated on the vial and carton after “EXP”. The expiry date

    refers to the last day of that month.

  • Do not store above 25°C.
  • When Remifentanil is made up it should be used straight away. Any unused solution should not be disposed

    of via wastewater or household waste. Your doctor or nurse will throw away any medicine that is no longer required. This will help protect the environment.

  • Store in the original package with this leaflet.

6 Contents of the pack and other information

What Remifentanil contains

The active substance is remifentanil hydrochloride.

The other ingredients are glycine, hydrochloric acid (for pH adjustment), and sodium hydroxide (for pH adjustment if needed).

What Remifentanil looks like and contents of the pack

Remifentanil for injection is a sterile, non-pyrogenic, preservative-free, white to off-white, lyophilised powder and is available in the following strengths:

  • 1 mg Remifentanil for injection, in 3 ml glass vials
  • 2 mg Remifentanil for injection, in 5 ml glass vials
  • 5 mg Remifentanil for injection, in 10 ml glass vials

The powder will be mixed with an appropriate fluid before being injected. When mixed to form a solution, Remifentanil is clear and colourless.

Each strength of Remifentanil is supplied in cartons containing 5 vials.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland Tel: + 44 1748 828 391

Manufacturer:

Avara Liscate Pharmaceutical Services S.p.A., Via Fosse Ardeatine, 2, 20050 Liscate (MI), Italy

Other formats:

To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:

0800 198 5000 (UK Only)

Please be ready to give the following information:

Product name Remifentanil 1 mg powder for concentrate for solution for injection/infusion

Remifentanil 2 mg powder for concentrate for solution for injection/infusion Remifentanil 5 mg powder for concentrate for solution for injection/infusion

Reference number PL 39699/0095

PL 39699/0096

PL 39699/0097

This is a service provided by the Royal National Institute of Blind People.

This leaflet was last revised in November 2023.

AW Version:

1

Page:

2 of 2

00002_0000152221
N/A

Market

United Kingdom

Number of Colours:

1

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 39699/0096

Last revision stated in the text: November 2023 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Ultiva (Remifentanil Hydrochloride) for injection 2 mg

Prescription needed? Yes, prescription-only medicine (POM)
Controlled drug
Yes, Schedule 2 of the Misuse of Drugs Regulations?
  • Controlled drugs are medicines that UK law controls more strictly because they can be misused or cause dependence. The Misuse of Drugs Regulations 2001 divide them into 5 schedules: schedule 1 has the strictest rules, schedule 5 the lightest.
  • Schedule 2 is the strictest group of prescribed medicines, for example strong opioid painkillers and medicines for ADHD.
  • A prescription is valid for 28 days and usually covers up to 30 days of treatment. It cannot be issued as a repeat dispensing prescription.
  • When you collect it, the pharmacist must check whether you are the patient and may ask for ID.
  • Travelling abroad: you can usually carry up to 3 months' supply. Take your prescription or a letter from your doctor to show it is yours, and check the rules of the country you are going to (GOV.UK).
  • Never give it to anyone else.
Active substance Remifentanil
Strength 2 mg
Pharmaceutical form Powder for solution for injection
How is it taken Intravenous
Pack sizes 5 vial
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. N Nervous system drugs
    1. N01 Anesthetics
      1. N01A Anesthetics, general
        1. N01AH Opioid anesthetics
          1. N01AH06 remifentanil
Marketing authorisation PL 39699/0096
Codes GTIN 5060598253665 · BNF 15010100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.